Camizestrant plus CDK4/6 inhibitors improved progression-free survival in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer compared to AI and CDK4/6 inhibitors. The SERENA-6 trial used ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify ...

Researchers reported that switching to a new drug combination — camizestrant plus a CDK4/6 inhibitor — soon after a blood test shows an emerging ESR1 mutation can keep the cancer under control ...

Reliable predictive biomarkers for immunotherapy response have eluded clinicians, who currently rely on PD-L1 immunohistochemistry, tumor mutational burden, and microsatellite stability tests ...

After being diagnosed with breast cancer at 39, I learned to advocate for myself, transforming fear into fierce resolve and purpose through every step. I reflect on how cancer has brought out ...

today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists ...

Discontinuation of the CDK4/6 inhibitor occurred in 1% of patients in both arms of the trial. SERENA-6 is the first global, double-blind, registrational Phase III trial to use a circulating tumor ...